Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105

Inclusion Criteria: 1. Clinically confirmed colorectal cancer patients; 2. It is planned to use the targeted drug regorafenib for the first time, and the initial dose is 120mg/d; 3. Performance Status score ≤3; 4. Age ≥18; 5, no intellectual and mental disorders, normal language expression ability, ability to judge their own symptoms 6\. Understand and agree to accept the treatment, and sign the informed consent. Exclusion Criteria: 1. Patients with skin reactions affected by simultaneous use of other targeted drugs (sorafenib, sunitinib, fruquintinib, etc.), chemotherapy drugs (capecitabine, doxorubicin, etc.) or hand-foot radiotherapy; 2. Patients with skin diseases such as eczema, psoriasis and tinea pedis at observed skin sites (namely hands and feet); Patients with skin allergic diseases; 3. Patients in the study who cannot cooperate with the continuation of this treatment; 4. Sudden changes in the patient's condition affected and interfered with the researcher